Anti-tumor necrosis factor (TNF) antibodies are successfully used in the therapy of
inflammatory bowel diseases (IBD). However, the molecular mechanism of action of these …

Ulcerative colitis (UC) and Crohn's disease (CD) are part of Inflammatory Bowel Diseases
(IBD) and have pathophysiological processes such as bowel necrosis and enteric neurons …

Tumor necrosis factor (TNF)-α is a potent pro-inflammatory and pathological cytokines in
inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases. Anti …

The use of biologic agents, particularly anti-tumor necrosis factor (TNF)-α, has revolutionized
the treatment of inflammatory bowel diseases (IBD), modifying their natural history. Several …

Biological treatment with tumor necrosis factor (TNF) inhibitors is successful in the
management of inflammatory bowel disease (IBD). All TNF inhibitors antagonize the pro …

BACKGROUND & AIMS: Anti–tumor necrosis factor (TNF) α antibodies are effective in
treating patients with Crohn's disease whereas soluble TNFα receptors have not shown …

BACKGROUND & AIMS: The anti–tumor necrosis factor (TNF) antibodies infliximab,
adalimumab, and certolizumab pegol have proven clinical efficacy in Crohn's disease. Here …

Several anti-tumour necrosis factor [TNF] blocking strategies have been evaluated in
patients with Crohn's disease. Compounds that have been tested included the full …

The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory
bowel diseases (IBDs). The overall objective was to better understand and explore primary …

Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being
evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable …